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ABSTRACT 
A simple, direct and cost-effective spectrophotometric method for determination of cefuroxime axetil (CRXA)  
in pure and tablet dosage forms was applied. This method is based on formation of ion-pair complex 
([CRXA]:[BTB]) between CRXA and bromothymol blue (BTB) in chloroform. Beer's law in the optimum 
experimental conditions using [CRXA]:[BTB] complex is valid within a concentration range of 2.00-50.00 μM 
(1.021–25.524 μg.mL
-1
). The developed method is applied for the determination of CRXA in pure and its 
commercial tablets without any interference from excipients with average assay of 96.8 to 101.6% and the 
results are in good agreement with those obtained by the HPLC reference method. Associated drugs 
(sulbactam and linesolid) with cefuroxime axetil are considered to be interfere, while metronidazole can be 
considered as non-interfere.  
Keywords: Cefuroxime axetil; Bromothymol blue; Ion-pair complex; Direct spectrophotometric method.  
1. INTRODUCTION 
Chemically cefuroxime axetil (CRXA) is (RS)-1-hydroxyethyl (6R,7R)-7-[2-(2-furyl) glyoxyl-amido]-3-
(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]-oct-2-ene-2-carboxylate,72-(Z)-(O-methyl-oxime), 1-acetate 
3-carbamate], its trade name is Ceftin, mol. mass of CRXA is 510.475 g/mol and 424.38 g/mol for cefuroxime 
(CRX), see Scheme 1 [1].  It is a broad spectrum, semi synthetic cephalosporin antibiotics which is administered 
for treating variety of bacterial infections such as case of pharyngitis, chronic bronchitis and infection of 
urinary tract as well as uncomplicated. It is a second generation cephalosporin and can be administered orally 
as well as in the parenteral dosage form. The mode of action of cefuroxime against the bacteria is upon 
inhibiting the bacterial wall synthesis by binding to one or many penicillin binding proteins [1,2].  
Bromothymol blue C27H28Br2O5S (BTB), acts as a weak acid in solution. It can thus be in protonated or 
deprotonated form, appearing yellow or blue, respectively. It is bluish green in neutral solution. The 
deprotonating of the neutral form results in a highly conjugated structure, accounting for the difference in 
colour. An intermediate of the deprotonating mechanism is responsible for the greenish color in neutral 
solution, mol. mass of 624.38 g/mol [3], see scheme 2. Bromothymol blue has been used as a reagent to form 
ion pair complexes with drugs [4].  
  
 
 
 
 
 
Scheme 1: Chemical structure of 
cefuroxime axetil (CRXA). 
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Various spectrophotometric [5-22], High Performance Liquid Chromatographic (HPLC), Reversed-phase high 
performance liquid chromatography (RP-HPLC), high performance thin layer chromatographic (HPTLC),  
micellar liquid chromatographic (MLC) [23-37] and voltammetric [38,39] methods have been reported for the 
determination of cefuroxime. 
Three simple accurate spectrophotometric methods have been developed for the estimation of cefuroxime 
axetil in bulk drug and its solid dosage forms. Method (A) was described about UV spectrophotometric 
measurement at maximum absorption of 277 nm while method (B) related to formation of green colored 
chromogen by utilizing the oxidative coupling reaction between 3-Methyl-2-benzothiozolidine hydrazone 
(MBTH) and cefuroxime axetil in presence of ferric chloride. It was measured at 624 nm against reagent blank. 
Method (C) was based on the formation of pink colored chromogen with para dimethyl amino 
cinnamaldehyde (PDAC) and it was measured at 537 nm. The beer's law obeyed at the concentration of 5-25 
µg.mL
-1
 , 1-5 µg.mL
-1
 and 2-10 µg.mL
-1
 for method A, B and C respectively. The developed analysis could be 
considered successfully for the determination of cefuroxime axetil in pharmaceutical formulation [17]. 
A simple, sensitive, accurate, precise and reproducible UV spectrophotometric method for determination of 
cefuroxime axetil using methanol as solvent was studied. In this method the simple UV spectrum of 
cefuroxime axetil in methanol was obtained which exhibits absorption maxima (λmax) at 278 nm. The 
quantitative determination of the drug was carried out at 278 nm and Beer’s law was obeyed in the range of 
(0.80-3.60) µg.mL
-1
. Proposed method was precise, accurate and cost effective [18]. 
A rapid and reproducible high performance liquid chromatographic method has been developed for the 
estimation of CRXA in its pure form as well as in pharmaceutical dosage forms. Chromatography was carried 
out on an ODS C18 column (150 x 4.6 mm x 5 μm length), using a mixture of methanol and 0.01M potassium 
dihydrogen orthophosphate buffer (60:40 v/v) at pH 2.0±0.05 as the mobile phase at a flow rate of 0.8 mL/min 
and the detection was done at 248 nm was developed and fully validated for the determination of CRXA. The 
retention time of the drug was 3.693 min. The method produced linear responses in the concentration range 
of 0.45 to 80 µg.mL
-1
 of CRXA. The method was successfully validated in accordance to The International 
Conference on Harmonization (ICH) guidelines and was found to be reproducible for analysis of the drug in 
parental preparations [27]. 
New analytical method has been developed for the determination of cefuroxime in pharmaceutical 
formulations. The method involves the application of high performance Liquid chromatography (HPLC) for the 
quantitative analysis of cefuroxime. Chromatography was carried out on a C18 column (150 × 4.6 mm, 3 μm) 
with mobile phase comprises of 2.47× 10
-4
 M Octane 1-sulfonic acid sodium salt: acetonitrile (65:35). The 
mobile phase was maintained to flow at a rate of 0.5 mL/min and the measurements were made at 254 nm. 
HPLC method has a shorter analysis time of 10 min. The developed method obeyed the Beer’s law in the range 
of 5- 300 μg.mL
-1 
[32]. 
In general, HPLC method is more accurate and acceptable. But the instrument is not available in all labs. So, 
the present work was undertaken with the aim to develop and validate an economic and rapid UV 
spectrophotometric method with high accuracy and precision. The method will be helpful for the routine 
estimation of cefuroxime axetil in pure form and in pharmaceutical formulations. 
 
Scheme 2: Chemical structure of Bromothymol blue  (BTB).         
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2. MATERIALS AND METHODS 
2.1. Equipment and Materials 
Spectrophotometric measurements were made in Spectro scan 80 DV UV-VIS spectrophotometer with 1 cm 
quartz cells. An ultrasonic processor model Power sonic 405 was used to sonicate the sample solutions. The 
diluter pipette model DIP-1 (Shimadzu), having 100 μL sample syringe and five continuously adjustable 
pipettes covering a volume range from 20 to 5000 μL (model Piptman P, GILSON). SARTORIUS TE64 electronic 
balance was used for weighing the samples. 
Cefuroxime axetil (99.9%) was supplied by Covalent laboratories private limited (India), Linezolid was provided 
as a gift sample by Balsam Pharma, Al Hawash, Homs, Syria. Sulbactam was provided as a gift sample by Ibn 
Hayyan Pharmaceuticals, Homs, Syria. Metronidazole was provided as a gift sample by AARTI DRUGS LIMITED 
Mumbai, India. BTB (97%) of analytical grade, chloroform were from Sigma-Aldrich. Na2CO3 and methanol 
extra pure were from MERCK. All other solvents and reagents were analytical grade chemicals.  
Tablet commercial formulations were used for the analysis of CRXA. The pharmaceutical formulations 
subjected to the analytical procedure were as the follows:  
(1) Zednad tablets, Diamond Pharma, Damascus suburb, Syria, each tablet contains 250 mg of CRX (equivalent 
to 300.7 mg CRXA) (Mfg. 4/2018, Exp. 4/2021)  and 500 mg of CRX (equivalent to 601.4 mg CRXA) (Mfg. 
3/2018, Exp. 3/2021).  
(2) Cefrocim tablets, Delta for medicaments, Aleppo, Syria, each tablet contains 250 mg of CRX (equivalent to 
300.7 mg CRXA) (Mfg. 6/2016, Exp. 6/2019) and 500 mg of CRX (equivalent to 601.4 mg CRXA) (Mfg. 7/2016, 
Exp. 7/2019). 
2.2 Standard stock solutions 
110
-3
 mol.L
-1
 of pure CRXA was prepared in chloroform. This solution was prepared by good mixing 5.11 mg 
of CRXA with 0.10 g of Na2CO3, adding 0.30 mL methanol, and solved in 7 mL chloroform using ultrasonic for 
15 min, filtered over a 10 mL flask and washed by the same solvent, then diluted to 10 mL with chloroform. 
The solution was stored in dark bottle and kept in the refrigerator for not more than a week. The stock 
solution was further diluted daily just before the use to obtain working solutions of CRXA in the concentration 
range 2.00-50.00 μM (1.021 – 25.524 μg.mL
-1
 of CRXA). 
Stock standard solution of bromothymol blue (BTB) 1x10
-2
 mol.L
-1 
:        
Accurately weighed 160.9 mg of bromothymol blue (BTB) was dissolved in chloroform into a volumetric flask 
(25 mL) and diluted up to mark with chloroform. 
2.3 Recommended Procedure     
Aliquots of 110
-3
 mol.L
-1
 CRXA solution (20, 50, 100, 150, 200, 300, 400 and 500 μL) containing: 2.00, 5.00, 
10.00, 15.00, 20.00, 30.00, 40.00 and 50.00 μM (1.021, 2.552, 5.105, 7.657, 10.210, 15.314, 20.419 and 25.524 
μg.mL
-1
) of CRXA were transferred into a series of 10 mL calibrated volumetric flasks. Then 0.100 mL of BTB 
solution (1x10
-2
 mol.L
-1
) was added. The volume was made up to the mark with solvent and the absorbance 
was measured at max 410 nm in chloroform, against a similar reagent blank. 
2.4 Procedure for pharmaceutical formulations  
Twenty tablets of each studied pharmaceutical formulation were weighed accurately, finely powdered and 
mixed well. An amount of the powder equivalent to the weight of tenth tablet was mixed well with 0.10 g of 
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Na2CO3, adding 0.30 mL methanol, and solved in 7 mL chloroform using ultrasonic for 15 min, filtered over a 
25 mL flask and washed by the same solvent, then diluted to 25 mL with chloroform. This solution contains the 
follows: 1.0 and 2.0 mg.mL
-1
 of CRX ( i.e. 1.203 and 2.406 mg.mL
-1
 of CRXA) for all studied pharmaceutical 
formulations contain 250 and 500 mg/tab, respectively. 
Five solutions were prepared daily by diluting 0.100 mL from each stock solution of pharmaceuticals for 
contents: 250 or 500 mg/tab, then 0.100 ml from stock standard solution of BTB was added and adjusted the 
volume up to 10 mL with chloroform (these solutions contain 10 or 20 μg.mL
-1
 of CRX respectively and 1x10
-4 
mol.L
-1
 of BTB; test solutions).  
3. RESULTS AND DISCUSSION 
3.1 The effect of solvent 
The effect of the solvents (acetonitrile, benzene, chloroform, dichloroethane, dichloromethane, ethylacetate 
and toluene) on absorbance of reagent (BTB), formed complex [CRXA]:[BTB] and the difference between them 
were studied. It was found that chloroform solvent was the best.  
3.2 Absorption Spectra 
UV-Vis spectra of CRXA, BTB and the formed complex CRXA:BTB solutions in chloroform was obtained. CRXA 
solutions do not absorb in the range 300-600 nm. BTB solutions have small absorption at max 412 nm (≈210 
L .mol
-1
.cm
-1 
in chloroform). [CRXA]:[BTB] complex solutions have maximum absorption at max 410 nm in 
chloroform, for the complex was L mol-1 cm-1,
 
see Figure 1 as example. 
  
 
 
 
 
 
 
 
3.3 Optimization of Variables 
The different experimental parameters affecting the spectrophotometric determination of CRXA through ion-
pair complex [CRXA]:[BTB] formation with BTB in chloroform was studied in order to determine the optimal 
conditions for the determination of CRXA. 
3.4 The effect of time and temperature 
The effect of time and temperature on the complex [CRXA]:[BTB] formation was studied within the ranges 5-
120 min and 15-45
o
C. It was found that the formed complex wasn't affected by time or temperature at those 
ranges.  
Fig.1. UV-Vis spectra in chloroform of: 1- 
0.5x10
-4 
mol.L
-1 
of CRXA; 2- 5.0x10
-4 
mol.L
-1
 of BTB; 3- 0.5x10
-4 
mol.L
-1 
ion-pair 
complex (0.5x10
-4 
mol.L
-1
 of CRXA with 
5x10
-4 
mol.L
-1
of BTB ); Blank is 5.0x10
-4
 
mol.L
-1
 of BTB, 4- 0.5x10
-4 
mol.L
-1 
ion-pair 
complex (0.5x10
-4 
mol.L
-1
 of CRXA with 
5x10
-4 
mol.L
-1
 of BTB); Blank is 
chloroform,  ℓ =1 cm. 
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3.5 The effect of BTB concentration 
The effect of BTB concentration on complex [CRXA]:[BTB] formation was investigated. It was observed that the 
absorbance of the formed complex increased coinciding with increasing the ratio of CBTB:CCRXA until the ratio 
(2:1).  
3.6 Stoichiometric Relationship 
3.6.1 The molar ratio method 
The composition of CRXA:BTB complex were determined by the molar ratio method and Job's method of 
continuous variation [40]. The stoichiometry of CRXA:BTB complex was studied by molar ratio method 
according to following equation: Amax=f([BTB]/[CRXA]) at max 410 nm in chloroform. It confirmed that the 
binding ratio of CRXA:BTB complex is equal to (1:1); where the concentration of CRXA was constant (50 M) 
and the concentrations of BTB changed from 0 to 200 M, see Figure 2. The formation constant of the ion pair 
complex [CRXA]:[ BTB] is 3.12x10
7
 in chloroform. 
 
  
 
 
 
 
3.6.2 The Job's method 
Continuous variation was utilized to check the composition of CRXA:BTB complex at max 410 nm in 
chloroform. The absorbance of the complex in used solvent were plotted against the mole fraction 
[BTB]/([CRXA]+[BTB]), where [CRXA]+[BTB]=50 M. The plot reached maximum value at a mole fraction of 0.5, 
see Figure 3. This indicated complex formation (CRXA:BTB) in the ratio of (1:1). The formation constant of the 
ion- pair complex [CRXA]:[BTB] is 3.5x10
7
. 
 
 
 
 
 
 
3.7 Mechanism of reaction 
Anionic dyes such as BTB form ion-pair complexes with the positively charged nitrogen-containing molecule. 
The colour of such dyes is due to the opening of lactoid ring and subsequent formation of quinoid group 
(deprotonated). CRXA is reacted with the dye at pH<3.8; (in pH>5.4 and alkaline solution BTB gives blue 
Fig.2. Molar ratio method to 
calculate binding ratio of 
CRXA:BTB complex at max 410 nm 
in chloroform ([CRXA]=50 M, 
blank is chloroform, ℓ =1 cm). 
 
Fig.3. Job's method of continuous variation 
to calculate binding ratio of CRXA:BTB 
complex at max 410 nm in chloroform 
([CRXA]+[BTB]=50M, blank is chloroform, 
ℓ =1 cm). 
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colour). Each drug-dye complex with two oppositely charged ions (positive on the drug and negative on the 
dye) behaves as a single unit held together by an electrostatic binding [41]. The suggested mechanism of 
CRXA-BTB ion-pair complex formation is shown in Scheme 3.  
 
Scheme 3: The possible reaction mechanism of [CRXA]:[BTB] complex formation. 
3.8 Calibration curve 
The calibration curve of CRXA in pure form through complexation with BTB showed excellent linearity over 
concentration range of 2.00-50.00 μM (1.021-25.524 μg.mL
-1
 ) in presence of 1.010
-4
 mol.L
-1 
of BTB with good 
correlation coefficient (R
2
=0.9996) in chloroform. Regression equation at max was as the follows: 
y=0.0241x+0.0039 in chloroform. Figures 4 showed the calibration curve of complex ([CRXA]:[ BTB]) in 
presence of 1.0×10
-4
 M of BTB as example. The spectra characteristics of the method such as the molar 
absorptivity () Beer's law, regression equation at max (y=a.x+b); where y=absorbance, a=slope, 
x=concentration of CRXA by μM,
 
b=intercept,
 
the correlation coefficient, limit of detection (LOD) and limit of 
quantification (LOQ) and the optimum conditions for spectrophotometric determination of CRXA through ion-
pair complex formation using BTB in chloroform is summarized in Table 1. 
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Fig 4: Calibration curve for determination of CRXA according to optimal conditions at λmax 410 nm (in present 
of 1.010
-4
 M of BTB) where CRXA:2.00–50.00 μM {Blank is BTB solution in chloroform 1.010
-4
 M; ℓ = 1 cm; a 
by μM and b by μg.mL
-1
 }. 
Table 1. The parameters established for spectrophotometric determination of CRXA by complex formation 
with BTB in chloroform. 
Parameters Operating values 
max of CRXA: BTB complex, nm 410 
Beer’s Law Limit, for CCRXA , μM 
 
2.00-50.00 
Beer’s Law Limit, for CCRXA , μg.mL
-1
  1.021 – 25.524 
Molar absorptivity of [CRXA]:[BTB] complex () L.mol-1.cm-1  24000
 
Regression equation for [CRXA]:[BTB] by μM at max =410 nm:  
Slope 0.0241 
Intercept 0.0039 
Correlation coefficient (R
2
) 0.9996 
LOD , μg.mL
-1  0.13 
LOQ , μg.mL
-1  0.39 
RSD%  4.2 
CBTB: CCRXA, M ≥2 
Stability  6 h 
Temperature of solution 25±5
o
C 
    n=5, t=2.776. 
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4. Analytical results 
Spectrophotometric determination of CRXA through complexation with BTB in chloroform within optimal 
conditions using calibration curve was applied. The results, summarized in Table 2, showed that the 
determined concentration of CRXA was rectilinear over the range of 2.00-50.00 μM (1.021–25.524 μg.mL
-1
)
 
, 
with relative standard deviation (RSD) not more than 4.2%. The results obtained from the developed method 
have been compared with the official HPLC method [27] and good agreement was observed between them. 
Table 2: Spectrophotometric determination of CRXA through complex formation with BTB within optimal 
conditions using calibration curve in chloroform (n=5, t=2.776). 
 
5. Applications 
The developed spectrophotometric method was applied to determine CRXA in some pharmaceutical 
preparations through complex formation by BTB in chloroform according to the optimal conditions. The 
results of quantitative analysis for CRXA in pharmaceutical preparations were summarized in Table 3. The 
Proposed method was simple, direct, specific and successfully applied to the determination of CRXA in 
pharmaceuticals without any interference from excipients. Average recovery ranged between 99.6 to 101.3%. 
The results obtained by this method agree well with the contents stated on the labels and were validated by 
HPLC method [27]. 
 
6. METHOD VALIDATION 
The developed method for simultaneous estimation of CRXA has been validated in accordance with the 
International Conference on Harmonization (ICH) guidelines [42]. 
x , g.mL-1  
HPLC [27] 
RSD% 
n
SDt
x
.
 , 
μg.mL
-1
 
x ±SD, 
μg.mL
-1 
(Found) 
(Taken) 
Xi, 
μg.mL
-1
 
Xi, 
μM 
1.094 4.2 0.977± 0.051 0.977±0.041 1.021 2.0 
2.500 3.9 2.460± 0.119 2.460±0.096 2.552 5.0 
5.082 3.7 5.002± 0.230 5.002±0.185 5.105 10.0 
7.682 3.6 7.756± 0.347 7.756±0.279 7.657 15.0 
10.346 3.5 10.299± 0.447 10.299±0.360 10.210 20.0 
15.027 3.4 15.383± 0.650 15.383±0.523 15.314 30.0 
20.580 3.3 20.680± 0.847 20.680±0.682 20.419 40.0 
25.046 3.1 25.235± 0.971 25.235±0.782 25.524 50.0 
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6.1 Specificity 
The specificity of the method was ascertained by analyzing standard CRXA in presence of excipients. There 
was no interference from the common excipients. 
Table 3: Determination of CRX, in some Syrian pharmaceutical preparations using spectrophotometric method 
through complex formation with BTB in chloroform, 
 max 410 nm, n=5, t=2.776).  
Tablet dosage 
form 
Label Claim  
of CRX, 
mg/tab. 
*Mean ±SD  
(CRX),  
mg/tab. 
 
RSD% Assay % 
Mean ±SD 
(CRX),  
mg/tab.  
by HPLC [27] 
Assay %, 
by HPLC [27] 
Zednad tablets  
250 254±9.6 3.8 101.6 253±7.1 101.2 
500 498±15.9 3.2 99.6 499±9.8 99.8 
Cefrocim tablets 
250 242±9.8 3.7 96.8 243±7.2 97.2 
500 506±16.2 3.2 101.2 504±9.6 100.8 
 
6.2 Linearity 
Several aliquots of standard stock solution of CRXA were taken in different 10 mL volumetric flask in presence 
of 1.010
-4
 mol.L
-1 
of BTB and diluted up to the mark with chloroform such that their final concentrations were 
2.00-50.00 μM (1.021–25.524 μg.mL
-1
) for CRXA. Absorbance was plotted against the corresponding 
concentrations to obtain the calibration graph, see Table 2. Linearity equations obtained were 
y=0.0241x+0.0039 (R
2
=0.9996) for the mentioned range. 
6.3 Precision and Accuracy 
The precision and accuracy of proposed method was checked by recovery study by addition of standard drug 
solution to pre-analyzed sample solution at three different concentration levels (80%, 100% and 120%) within 
the range of linearity for CRXA. The basic concentration level of sample solution selected for spiking of the 
CRXA standard solution was 10.210 μg.mL
-1
. The Proposed method was validated statistically and through 
recovery studies and was successfully applied for the determination of CRXA in pure and dosage forms with 
percent recoveries ranged from 99.6% to 101.3%, see Table 4.  
Table 4: Results of recovery studies (n=5). 
Level Recovery% 
80% 99.6 
100% 99.4 
120% 101.3 
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6.4 Repeatability  
The repeatability was evaluated by performing 10 repeat measurements for 15.0 μM (7.657 μg.mL
-1
) of CRXA 
using the studied method under the optimum conditions. The found amount of CRXA ( x ± SD) 15.191±0.516 
μM (7.756±0.264 μg.mL
-1
) and the percentage recovery was found to be 101.3±3.4. These values indicate that 
the proposed method has high repeatability for CRXA analysis.  
6.5 Robustness 
The robustness of the method adopted is demonstrated by the constancy of the absorbance with the 
deliberated minor change in the experimental parameters such as the change in the concentration of 
excipients, CBTB (10±5%), temperature (25±5
o
C), stability (6±0.5 h) and reaction time (5±1 min), see Table 5 
which indicates the robustness of the proposed method. The absorbance was measured and assay was 
calculated for five times. 
Table 5: Robustness of the proposed spectrophotometric method, 
(n=5, t=2.776). 
Experimental parameter 
variation 
Average recovery (%)  
CCRXA 
2.552 μg.mL
-1
 15.314 μg.mL
-1 
Temperature 
20
o
C 
30
o
C 
 
99.8 
100.1 
 
99.9 
100.4 
Stability 
5.5 h 
6.5 h 
 
99.7 
100.1 
 
99.9 
100.3 
Reaction time 
4.0 min 
6.0 min 
 
100.2 
100.4 
 
100.1 
100.0 
                           
 
6.6 Sensitivity (LOD and LOQ) 
The sensitivity of the method was evaluated by determining the LOD and LOQ. The values of LOD and LOQ for 
CRXA are 0.13 and 0.39 μg.mL
-1
, respectively. 
6.7 The homogenization of tablets  
The homogenization of tablets in terms of the weight and the amount of drug was studied. We found that the 
mean weight and amount drug in the tablets was 0.7544 ± 0.0046 g (i.e. ±0.61%), 0.8577 ± 0.039 g (i.e. ±4.6%) 
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for Cefrocim tablets (250 and 500 mg/tab) and 0.4486 ± 0.0021g (i.e. ±0.47%) and 0.8577 ± 0.0046 g (i.e. 
±0.54%) for Zednad tablets (250 and 500 mg/tab), respectively. While the mean amount drug in the tablets 
was 254±1.82 mg/tab (i.e. ±0.73%) and 497±21 mg/tab (i.e. ±4.2%) for Zednad tablets (250 and 500 mg/tab) 
and 244±6.98mg/tab (i.e. ±2.8%) and 505±5.2 mg/tab (i.e. ±1.03%) for Cefrocim tablets (250 and 500 mg/tab), 
respectively; which shows that homogeneity of tablets is good. 
6.8 Interferences  
The presence of 1:1 sulbactam or linesolid in the tablet interfere the determination of cefuroxime axetil (or 
cefuroxime) by 24% and 32% , respectively. While metronidazole can be considered as non-obstructive 1:1 
(disability less than 5%) does not interferes.  
7. CONCLUSION 
The developed spectrophotometric method is simple, direct (extraction-free) and cost-effective for the  
determination of CRXA in pure and tablet dosage forms was applied. This method is based on formation of 
ion-pair complex between CRXA and BTB in chloroform ([CRXA]:[BTB]). Beer’s law in the optimum 
experimental conditions using [CRXA]:[BTB] complex is valid within a concentration range of 1.021–25.524 
μg.mL
-1
. The developed method is applied for the determination of CRXA in pure and its commercial tablets 
without any interference from excipients with average assay of 96.8 to 101.6%. Associated drugs (sulbactam or 
linesolid) with cefuroxime are considered to be interfere, while metronidazole can be considered as non-
interfere.  
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